Search

Your search keyword '"Jongheon Jung"' showing total 2 results
Start Over Author "Jongheon Jung" Journal scientific reports
2 results on '"Jongheon Jung"'

1. High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

Author

Jongheon Jung, Hyewon Lee, Ja Yoon Heo, Myung Hee Chang, Eunyoung Lee, Weon Seo Park, Ju-Hyun Park, and Hyeon-Seok Eom

Subjects
Medicine, Science
Abstract

Abstract The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminative cut-off for identifying patients with high CAR values (73/141 patients, 51.8%). During a median follow-up of 32.5 months, the high CAR group had significantly poorer complete response to induction therapy (64.4% vs. 92.6%; p 0.158 also showed worse 3-year OS (47.9% vs. 87.2%, p = 0.0035) and 3-year PFS (36.1% vs. 82.1%, p = 0.0011). A high CAR remained significantly associated with poor outcomes for > 60-year-old patients (OS: p = 0.0038, PFS: p = 0.0015) and younger patients (OS: p = 0.0041, PFS: p = 0.0044). Among older patients, a high CAR value also predicted non-relapse mortality (p = 0.035). Therefore, the CAR might complement the International Prognostic Index in DLBCL cases.

Published
2021
Full Text
View/download PDF

2. High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

Author

Hyeon-Seok Eom, Weon Seo Park, Jongheon Jung, Ja Yoon Heo, Hye Won Lee, Ju-Hyun Park, Myung Hee Chang, and Eun Young Lee

Subjects
0301 basic medicine, Pre treatment, Male, Gastroenterology, 0302 clinical medicine, International Prognostic Index, Induction therapy, Antineoplastic Combined Chemotherapy Protocols, Cancer, Multidisciplinary, biology, Middle Aged, Neoplasm Proteins, Survival Rate, C-Reactive Protein, Oncology, Vincristine, 030220 oncology & carcinogenesis, Medicine, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab, medicine.medical_specialty, Science, Serum Albumin, Human, Article, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Cyclophosphamide, Aged, Retrospective Studies, business.industry, C-reactive protein, Albumin, Retrospective cohort study, medicine.disease, Lymphoma, 030104 developmental biology, Doxorubicin, biology.protein, Prednisone, business, Diffuse large B-cell lymphoma, Biomarkers, Follow-Up Studies
Abstract

The C-reactive protein-to-albumin ratio (CAR) has not been assessed in diffuse large B cell lymphoma (DLBCL, the most common non-Hodgkin lymphoma). This retrospective study evaluated the prognostic value of CAR in 186 DLBCL patients. A CAR value of 0.158 was selected as the most discriminative cut-off for identifying patients with high CAR values (73/141 patients, 51.8%). During a median follow-up of 32.5 months, the high CAR group had significantly poorer complete response to induction therapy (64.4% vs. 92.6%; p 0.158 also showed worse 3-year OS (47.9% vs. 87.2%, p = 0.0035) and 3-year PFS (36.1% vs. 82.1%, p = 0.0011). A high CAR remained significantly associated with poor outcomes for > 60-year-old patients (OS: p = 0.0038, PFS: p = 0.0015) and younger patients (OS: p = 0.0041, PFS: p = 0.0044). Among older patients, a high CAR value also predicted non-relapse mortality (p = 0.035). Therefore, the CAR might complement the International Prognostic Index in DLBCL cases.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results